Connect Biopharma to Host First Half 2021 Financial Results Conference Call on September 1, 2021
August 25 2021 - 8:00AM
Connect Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect
Biopharma" or the “Company”), a global clinical-stage
biopharmaceutical company dedicated to improving the lives of
patients with chronic inflammatory diseases through the development
of therapies derived from T cell-driven research, today announced
that it will report financial results for the first half ended June
30, 2021 after the market closes on Tuesday, August 31, 2021.
Connect Biopharma management will host a webcast and conference
call to review its results on Wednesday, September 1, 2021,
beginning at 8:30 am Eastern Time.
The conference call can be accessed using the
following
information:Webcast: https://edge.media-server.com/mmc/p/d8b5cvafU.S.:
844-646-2698Outside of U.S.:
918-922-6903Conference ID: 5567966
A replay of the call will be available for two
weeks by dialing 855-859-2056 for U.S. callers or 404-537-3406 for
international callers and using Conference ID: 5567966. The webcast
will also be available in the “Investors” section of the Company’s
website following the completion of the call.
About Connect Biopharma Holdings
LimitedConnect Biopharma Holdings Limited is a global
clinical-stage biopharmaceutical company dedicated to improving the
lives of patients living with chronic inflammatory diseases through
the development of therapies derived from our T cell-driven
research.
Our lead product candidate, CBP-201, is an
antibody designed to target interleukin-4 receptor alpha (IL-4Rα)
and is currently being evaluated in clinical trials for the
treatment of atopic dermatitis (AD) and asthma and in development
for chronic rhinosinusitis with nasal polyps (CRSwNP). Our second
lead product candidate is CBP-307, a modulator of a T cell receptor
known as sphingosine 1-phosphate receptor 1 (S1P1) that is in
development for the treatment of ulcerative colitis (UC) and
Crohn’s disease (CD). Furthermore, we are developing CBP-174, a
peripherally restricted antagonist of histamine receptor 3, for the
treatment of pruritus associated with skin inflammation.
With headquarters in China, additional
operations in the United States and Australia, and clinical
development activities in those geographies as well as Europe,
Connect Biopharma is building a rich global pipeline of internally
designed, wholly owned small molecules and antibodies targeting
several aspects of T cell biology. For additional information about
Connect Biopharma, please visit our website at
www.connectbiopharm.com.
IR/PR CONTACTS: Lazar FINN Partners David
Carey (IR) T: +1-(212)
867-1768david.carey@finnpartners.comErich Sandoval
(Media) +1-(646) 871-8482 or +1-(917)
497-2867erich.sandoval@finnpartners.com
Corporate
Contacts:info@connectpharm.com
Connect Biopharma (NASDAQ:CNTB)
Historical Stock Chart
From Aug 2024 to Sep 2024
Connect Biopharma (NASDAQ:CNTB)
Historical Stock Chart
From Sep 2023 to Sep 2024